CN Patent

CN1761676A — 杂芳基5－硫代－β－D－吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药

Assigned to Taisho Pharmaceutical Co Ltd · Expires 2006-04-19 · 20y expired

What this patent protects

本发明提供一种显示SGLT2的活性抑制作用、由下式表示的杂芳基5－硫代－β－D－吡喃葡糖苷化合物或其药学上可接受的盐或其水合物、及含有上述物质作为有效成分的医药品，特别是糖尿病、糖尿病相关疾病或糖尿病性合并症的预防或治疗药。

USPTO Abstract

本发明提供一种显示SGLT2的活性抑制作用、由下式表示的杂芳基5－硫代－β－D－吡喃葡糖苷化合物或其药学上可接受的盐或其水合物、及含有上述物质作为有效成分的医药品，特别是糖尿病、糖尿病相关疾病或糖尿病性合并症的预防或治疗药。

Drugs covered by this patent

Patent Metadata

Patent number
CN1761676A
Jurisdiction
CN
Classification
—
Expires
2006-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Taisho Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.